Related Experiment Video

Updated: Jan 3, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.0K

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma

Yongting Lai1, Bing Feng2, Mubalake Abudoureyimu2

  • 1Department of Medical Oncology, Nanjing School of Clinical Medicine, Jinling Hospital, Southern Medical University, Nanjing, China.

Frontiers in Oncology
|November 22, 2019
PubMed

Insights

Sorafenib is a key drug for advanced liver cancer (HCC), but resistance is a problem. This study reviews how non-coding RNAs (ncRNAs) contribute to sorafenib resistance in HCC and suggests future strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Sorafenib, an oral multi-target anti-tumor drug, revolutionized advanced hepatocellular carcinoma (HCC) treatment since 2007.
  • Drug resistance remains a significant challenge limiting the clinical efficacy of sorafenib in HCC patients.

Purpose of the Study:

  • To summarize recently reported mechanisms of non-coding RNAs (ncRNAs) in sorafenib resistance in HCC.
  • To discuss potential therapeutic strategies involving ncRNAs for overcoming sorafenib resistance in HCC.

Main Methods:

  • Literature review of studies investigating ncRNAs (miRNAs, lncRNAs) and their roles in HCC sorafenib resistance.
  • Analysis of identified mechanisms linking ncRNAs to sorafenib resistance pathways.

Main Results:

  • Non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are increasingly recognized for their critical roles in various cancers, including HCC.
  • Specific ncRNAs have been implicated in the development and progression of sorafenib resistance in HCC through diverse molecular mechanisms.

Conclusions:

  • Understanding the intricate mechanisms of ncRNAs in HCC sorafenib resistance is crucial for developing novel therapeutic approaches.
  • Targeting specific ncRNAs presents a promising strategy to enhance the effectiveness of sorafenib and combat resistance in advanced HCC.
Keywords:
hepatocellular carcinoma (HCC)long non-coding RNAs (lncRNAs)microRNAs (miRNAs)non-coding RNAs (ncRNAs)sorafenib resistance

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.2K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.4K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K